Insider · CIK 0001783451
Pierre Jacquet
Files at MREO (Mereo BioPharma Group plc). First filing -, latest -.
In brief
Pierre Jacquet files SEC Form 4 as director at MREO (Mereo BioPharma Group plc). No open-market trade is on file; the transactions below are grants, exercises and other rows that carry no view on the price.
A track record needs three past buys with six months of prices behind them; Pierre Jacquet has 0, so none is measured yet.
Signals
This insider’s open-market buys and sells, scored.
Transactions
Every row this insider has filed, 4 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Feb 26, 2026 | MREO Mereo BioPharma Group plc | AGrant or award Share Options (Right to buy)derivative | +66,000 | $0.00 | $0 | 66,000 | Feb 27, 2026 |
| Feb 26, 2026 | MREO Mereo BioPharma Group plc | AGrant or award Deferred Restricted Stock Unitsderivative | +106,848 | - | - | 106,848 | Feb 27, 2026 |
| Feb 5, 2025 | MREO Mereo BioPharma Group plc | AGrant or award Share Options (Right to buy)derivative | +55,000 | $0.00 | $0 | 55,000 | Feb 6, 2025 |
| Feb 5, 2025 | MREO Mereo BioPharma Group plc | AGrant or award Deferred Restricted Stock Unitsderivative | +15,243 | - | - | 15,243 | Feb 6, 2025 |
Questions about Pierre Jacquet
Answered from the filings on this page, as of the latest one.
Is Pierre Jacquet buying or selling?
Pierre Jacquet has no open-market buy or sell on SEC Form 4; the filings on record are grants, exercises and other transactions.
How did Pierre Jacquet's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Pierre Jacquet has 0.
Where does Pierre Jacquet file Form 4?
Pierre Jacquet has filed Form 4 at MREO (Mereo BioPharma Group plc). A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.